Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgerySierra Health and Life Leqembi Coverage Update | O…
    Ask Trek AI about this page
    Modifiedsierra health and lifePolicy 2026D0125D

    Leqembi (lecanemab-irmb) – Medical Benefit Coverage Criteria

    Customize your policy alerts

    Sign up for sierra health and life Policy 2026D0125D alerts

    Get alerted when Policy 2026D0125D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Covers medical-benefit administration of intravenous Leqembi for members when criteria for treatment of early Alzheimer's disease are met; distinguishes formulation obtained under pharmacy benefit. Affects prescribers and prior authorization reviewers.

    Policy Summary
    Payersierra health and life
    PolicyLeqembi (lecanemab-irmb) – Medical Benefit Coverage Criteria
    Policy CodePolicy 2026D0125D
    Change TypeModified coverage criteria and authorization duration
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization (J0174) and submit baseline cognitive testing and amyloid biomarker evidence; initial authorization limited to 12 months.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    Changed initial authorization duration from 'no more than 6 months' to 'no more than 12 months'.

    Revised coverage criteria for continuation of therapy; removed requirement that the patient must have MCI due to AD, mild dementia due to AD, or progressed to moderate/severe dementia with prescriber attestation.

    Archived previous policy version 2025D0125C.

    12 momax initial auth
    J0174HCPCS
    MMSE 20-30baseline cognitive range
    Baseline MRIrequired imaging
    Excludedconcomitant Aβ mAbs

    Coverage Criteria for Leqembi (lecanemab-irmb)

    Initial Therapy Criteria

    Leqembi is covered when ALL of the following are met for initial therapy:

    Diagnosis based on NIA-AA criteria of either mild cognitive impairment (MCI) due to Alzheimer's disease OR mild dementia due to Alzheimer's disease.

    Based on NIA-AA criteria as stated in policy.

    Biomarker confirmation: Presence of amyloid beta pathology confirmed by positive amyloid PET OR cerebrospinal fluid (CSF) biomarker testing indicative of beta-amyloid accumulation (e.g., Aβ42/40 ratio, p-tau181/Aβ42, t-tau/Aβ42).

    Documented by imaging or CSF per policy requirements.

    Baseline brain MRI: Baseline brain magnetic resonance imaging (MRI) completed within 12 months prior to initiating treatment.within 12 months

    Policy requires baseline MRI within 12 months before start of therapy.

    Baseline cognitive score documentation: Submission of medical records documenting one of the following baseline cognitive scores: MMSE 20–30 OR MoCA 17–30 OR SLUMS 17–30.MMSE 20-30; MoCA 17-30; SLUMS 17-30

    Acceptable test score ranges required for initiation.

    Anticoagulant considerations: Either the patient is not currently taking an anticoagulant OR if the patient is taking an anticoagulant, the prescriber documents that counseling occurred about increased cerebral hemorrhage risk and attests that shared decision-making occurred.

    Policy specifies counseling and attestation when anticoagulants are used.

    Recent intracerebral hemorrhage: No history of intracerebral hemorrhage within the previous year prior to initiating treatment.within 1 year

    Policy excludes recent intracerebral hemorrhage.

    ARIA and ApoE counseling: Counseling provided on ARIA risks (ARIA-E and ARIA-H) and testing for apolipoprotein E (ApoE ε4) status has been offered; prescriber attests that shared decision-making regarding initiation occurred.

    Counseling and offer of ApoE ε4 testing required per policy.

    Prescriber specialty and dosing: Prescribed by a neurologist, geriatric psychiatrist, or geriatrician who specializes in treating dementia, and dosing is in accordance with the FDA-approved labeling.

    Policy requires specialist prescriber and FDA-consistent dosing.

    Initial authorization duration: Initial authorization limited to no more than 12 months.<= 12 months

    Policy revision sets maximum initial authorization to 12 months.

    Continuation of Therapy Criteria

    For continuation (reauthorization) of therapy, ALL of the following must be met:

    Diagnosis of Alzheimer's disease.

    Continuation requires ongoing AD diagnosis per policy.

    Follow-up MRI documentation: Submission of medical records confirming a follow-up brain MRI has been completed after initiation of therapy.

    Follow-up MRI is required for continuation requests.

    ARIA result-based continuation: Either ARIA has not been observed on MRI OR if ARIA has been observed on MRI then ALL of the following are met: prescriber attests continuation is appropriate based on clinical symptom severity AND either follow-up MRI demonstrates radiographic resolution/stabilization OR prescriber attests continuation is appropriate based on the radiographic severity of ARIA.

    Continuation decisions consider presence and severity/resolution of ARIA.

    Concomitant therapy and prescriber/dosing requirements:

    Not Medically Necessary / Unproven Indications

    Other indications: Leqembi is unproven and not medically necessary for any indication other than Alzheimer's disease.

    Policy explicitly states noncoverage for other indications.

    Initial Coverage (Inferred from Trials)

    Covered when ALL of the following are met (as inferred from trial populations and indication):

    Population: Patient has mild cognitive impairment due to Alzheimer's disease or mild dementia due to Alzheimer's disease (population in which treatment was initiated in clinical trials).

    CLARITY AD and Study 201 enrolled patients with early AD (MCI or mild dementia); FDA indicates initiation in this population.

    Biomarker evidence: Evidence of amyloid pathology (e.g., positive amyloid PET or CSF biomarker abnormalities) consistent with enrollment criteria in CLARITY AD and Study 201.

    Trials required amyloid evidence by PET or CSF.

    Dosing: Planned dosing consistent with trials: intravenous lecanemab 10 mg/kg every 2 weeks for the core study period.10 mg/kg IV every 2 weeks

    Dose used in CLARITY AD and Study 201.

    Use of Leqembi in combination with other amyloid-beta monoclonal antibodies is explicitly excluded. Treatment administered concurrently with another Aβ monoclonal antibody (for example, Kisunla) will not meet coverage criteria and may trigger non-coverage or denial.

    Coverage of Leqembi is subject to the member-specific benefit plan terms and any applicable state or federal mandates. Review the member’s certificate of coverage and applicable mandates prior to authorization; where a mandate or the member’s benefit document conflicts with this policy, the mandate or the member specific benefit plan governs and may result in exclusion of treatment under this policy.

    Leqembi is considered unproven and not medically necessary for any indication other than Alzheimer's disease. Requests for use outside the diagnosis of Alzheimer’s disease do not meet the policy’s coverage criteria.

    Use of Leqembi in patient populations without evidence of amyloid pathology or in later-stage disease lacking trial support is not supported. Clinical trial experience and prior anti-Aβ development failures identify lack of demonstrated efficacy when patients without confirmed Aβ pathology were enrolled or when treatment was started at later stages with significant irreversible neurodegeneration; such uses are therefore considered unproven.

    Coding — HCPCS and Diagnosis Codes

    Applicable HCPCS/Drug CodesHCPCS
    J0174Injection, lecanemab-irmb, 1mg.
    Relevant Diagnosis CodesICD-10
    G30.0Alzheimer's disease with early onset.
    G30.1Alzheimer's disease with late onset.
    G30.8Other Alzheimer's disease.
    G30.9Alzheimer's disease, unspecified
    Acceptable baseline cognitive test score ranges — initiation
    MMSE rangeMini-Mental State Examination (MMSE) score of 20 to 30 documented in medical records
    MoCA rangeMontreal Cognitive Assessment (MoCA) score of 17 to 30 documented in medical records
    SLUMS rangeSaint Louis University Mental Status (SLUMS) score of 17 to 30 documented in medical records

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for IV Leqembi (billing code J0174). Initial authorization will be for no more than 12 months when all coverage criteria are met. Reauthorization (continuation) requests also require documentation and will be for no more than 12 months.

    • Affected code: J0174 (Injection, lecanemab-irmb, 1 mg)
    • Initial and reauthorization durations: ≤ 12 months
    Note

    Check Member Benefit and Plan Conflicts

    Before initiating therapy, verify the member-specific benefit plan document to confirm that this medical benefit is covered for the member. Some plans or state mandates may alter coverage or require different handling of experimental/unproven therapies. Coverage decisions must follow the member specific benefit plan and any applicable federal or state mandates.

    • Confirm member benefit and any state or plan mandates before submitting authorization

    Definitions and Clinical Measures

    ARIA — Definitions and relevance
    ARIA-E definitionAmyloid-related imaging abnormality — edema/effusion (ARIA-E) associated with anti-amyloid therapies; may present with headache, dizziness, visual disturbance, nausea or vomiting and is monitored by MRI
    ARIA-H definitionAmyloid-related imaging abnormality — hemosiderin deposition and microhemorrhages (ARIA-H) identified on MRI and relevant to hemorrhage risk
    Relevance to therapyPatients must be counseled on ARIA risks and follow-up brain MRI is required after treatment initiation to guide continuation decisions
    Cognitive tests and staging — descriptions and scoring ranges
    MMSE (0–30)Mini-Mental State Examination: global cognitive status test scored 0–30; lower scores indicate greater impairment; used for baseline documentation (acceptable 20–30)
    MoCA (0–30)

    Background

    Alzheimer’s disease is characterized by progressive cognitive decline associated with accumulation of amyloid-beta plaques and tau neurofibrillary tangles; amyloid accumulation begins years to decades before clinical symptoms. Leqembi (lecanemab-irmb) is a humanized IgG1 monoclonal antibody that targets aggregated soluble and insoluble forms of amyloid-beta to reduce plaque burden. Clinical trial data informed the policy focus on treating patients with mild cognitive impairment or mild dementia due to Alzheimer's disease and require documentation of amyloid pathology and baseline imaging prior to initiation.

    Revision History and Policy Changes

    2026-02-01policy_revisionLatest

    Changed initial authorization duration from 'no more than 6 months' to 'no more than 12 months' and revised continuation criteria by removing the requirement that the patient be specifically attested as MCI due to AD, mild dementia due to AD, or progressed to moderate/severe dementia with prescriber attestation.

    (archived prior version)archival

    Archived previous policy version 2025D0125C.

    Policy Summary
    Payersierra health and life
    PolicyLeqembi (lecanemab-irmb) – Medical Benefit Coverage Criteria
    Policy CodePolicy 2026D0125D
    Change TypeModified coverage criteria and authorization duration
    Effective DateFeb 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization (J0174) and submit baseline cognitive testing and amyloid biomarker evidence; initial authorization limited to 12 months.
    SourceLink
    On This Page
    Coverage Criteria for Leqembi (lecanemab-irmb)Coding — HCPCS and Diagnosis CodesProvider Actions, Documentation, and AuthorizationDefinitions and Clinical MeasuresBackgroundRevision History and Policy Changes
    Not used in combination with other Aβ monoclonal antibodies for Alzheimer's disease (e.g., Kisunla); prescribed by an appropriate dementia specialist and dosed per FDA labeling.

    Concurrent use with other Aβ mAbs is excluded and specialist prescriber/dosing required.

    Reauthorization duration: Reauthorization limited to no more than 12 months.<= 12 months

    Policy limits each reauthorization to 12 months.

    Authorization duration (inferred): Initial authorization for treatment not to exceed 12 months per policy revision.<= 12 months

    Policy revision updated initial authorization maximum to 12 months.

  1. Where plan language conflicts with mandates, mandates supersede
  2. Documentation Required

    Documentation Required: Baseline Cognitive/Biomarker and Follow-up MRI/Counseling

    Submission of baseline cognitive testing and evidence of amyloid pathology is required with the initial authorization request. For continuation requests, submit follow-up MRI results and documentation of ARIA counseling or clinical rationale as applicable.

    • Baseline cognitive test score documented: MMSE 20–30, MoCA 17–30, or SLUMS 17–30
    • Evidence of amyloid pathology: positive amyloid PET or CSF biomarker abnormalities (e.g., Aβ42/40 ratio, p-tau181/Aβ42)
    • Baseline brain MRI completed within 12 months prior to initiating treatment
    • For continuation: submission of follow-up brain MRI performed after treatment initiation
    • For continuation when ARIA observed: prescriber attestation that continuation is appropriate based on clinical severity and either radiographic resolution/stabilization or documented rationale for continued treatment
    Denial Risk

    Concomitant Aβ mAb Use — Denial Risk

    Leqembi must not be used concomitantly with other amyloid‑beta monoclonal antibodies. Requests indicating combined use with another Aβ mAb (for example, Kisunla) will be denied/not covered.

    • Concomitant use with other Aβ mAbs (e.g., Kisunla) is a denial condition
    • Ensure medication history and current therapies are documented to show no concurrent Aβ mAb use
    Billing Rule

    Prescriber, Dosing, and Utilization Tools

    Prescriptions should be written by an appropriate specialist and dosing must follow FDA labeling. Use of utilization management tools and plan-specific benefit rules may affect coverage decisions.

    • Prescriber requirement: neurologist, geriatric psychiatrist, or geriatrician who specializes in dementia
    • Leqembi dosing must follow FDA‑approved labeling
    • UnitedHealthcare and delegated plans may use third-party tools (e.g., InterQual) to assist in administration
    • Member benefits, state mandates, and other utilization management tools may alter coverage — always check member-specific documents
    Montreal Cognitive Assessment: 30-point screening test more sensitive for MCI; acceptable baseline range 17–30
    SLUMSSaint Louis University Mental Status exam: cognitive screening with acceptable baseline range 17–30 documented for initiation
    CDR‑SBClinical Dementia Rating – Sum of Boxes (CDR‑SB) ranges 0–18 used to stage disease severity; 4.5–9.0 corresponds to mild dementia and is referenced for disease staging
    Alzheimer's disease clinical stages (0–6) — numeric staging definitions
    Stage 0Asymptomatic with normal biomarkers; no evidence of clinical change
    Stage 2–3 (early symptomatic)Stage 2: transitional decline with minimal impact on daily function; Stage 3: cognitive impairment with early functional impact but independent for basic ADLs
    Stage 4–6 (dementia progression)Stage 4: dementia with mild functional impairment (instrumental ADL impairment); Stage 5: moderate impairment requiring assistance with basic ADLs; Stage 6: severe impairment with complete dependence
    Leqembi (lecanemab-irmb) — definition and mechanism
    Drug identityLeqembi (lecanemab-irmb): a humanized IgG1 monoclonal antibody
    TargetDirected against aggregated soluble and insoluble forms of amyloid beta (Aβ)
    Mechanism of actionBinds aggregated Aβ to reduce amyloid plaques in the brain, addressing a defining pathophysiological feature of Alzheimer's disease